EUVIMEDEUVIMED entdecken
Open Access

Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer

Meghan J Mooradian, Ling Cai, Alice Wang, Yao Qiao, Pratibha Chander, Ryan M Whitaker

JAMA Network Open · 22.04.2024 · 7 (4) · e247542

DOI: 10.1001/jamanetworkopen.2024.7542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 22.04.2024. Verfasst von Meghan J Mooradian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Antibodies, Monoclonal. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The PACIFIC trial established consolidation durvalumab as the standard of care following chemoradiotherapy (CRT) for patients with unresectable stage III non–small cell lung cancer (NSCLC). Understanding its benefit in routine US clinical practice is critical.

Objective

To report characteristics, treatment patterns, and outcomes of patients who did or did not receive durvalumab. Design, Setting, and Participants Two prespecified cohorts were curated in this retrospective cohort study (SPOTLIGHT). Deidentified patient-level data from a US database (Flatiron Health) were analyzed. Patients had unresectable stage III NSCLC, were diagnosed on or after January 1, 2011, had 2 or more visits on or afterward, and received CRT. Data were analyzed from May 2021 to October 2023. Exposures Patients started durvalumab after CRT (durvalumab cohort) or ended CRT without durvalumab (nondurvalumab cohort) by June 30, 2019, to allow 15 or more months of follow-up from CRT end. Main Outcomes and Measures End points included progression-free survival (PFS), overall survival (OS), time to first subsequent therapy or death (TFST), and time to distant metastasis or death (TTDM).

Results

The durvalumab cohort included 332 patients (median [IQR] age, 67.5 [60.8-74.0] years; 187 were male [56.3%], 27 were Black [8.7%], 33 were other races [10.7%], and 249 were White [80.6%]) and the nondurvalumab cohort included 137 patients (median (IQR) age, 70.0 [64.0-75.0] years; 89 [65.0%] were male, 11 [8.9%] were Black, 19 [15.4%] were other races, and 93 [75.6%] were White). Most patients had a smoking history (durvalumab, 316 patients [95.2%] and nondurvalumab, 132 patients [96.4%]) and Eastern Cooperative Oncology Group performance status 0 through 1 (durvalumab, 251 patients [90.9%] and nondurvalumab, 88 patients [81.5%]). Median (IQR) CRT duration was 1.6 (1.4-1.8) months for the durvalumab cohort and 1.5 (1.4-1.8) months for the nondurvalumab cohort. Median time to durvalumab discontinuation was 9.5 months (95% CI, 7.8-10.6 months). Median TFST and TTDM were not reached (NR) in the durvalumab cohort and 8.3 months (95% CI, 4.8-11.8 months) and 11.3 months (95% CI, 6.4-14.5 months), respectively, in the nondurvalumab cohort. Median PFS and OS were 17.5 months (95% CI, 13.6-24.8 months) and NR in the durvalumab cohort and 7.6 months (95% CI, 5.2-9.8 months) and 19.4 months (95% CI, 11.7-24.0 months) in the nondurvalumab cohort. In Cox regression analyses of patients who completed concurrent CRT without progression, durvalumab was associated with a lower risk of progression or death (hazard ratio [HR], 0.36; 95% CI, 0.26-0.51) and lower risk of death (HR, 0.27; 95% CI, 0.16-0.43), adjusted for prior platinum agent and patient characteristics. Conclusions and Relevance In this cohort study, findings were consistent with PACIFIC, and durvalumab was associated with a lower risk of progression and/or death. Further investigation is warranted to explain why patients did not receive durvalumab after its approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyAntibodies, MonoclonalHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAntineoplastic Agents, ImmunologicalNeoplasm StagingCohort Studies

Substanzen

durvalumabAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston.
  • AstraZeneca, Gaithersburg, Maryland.
  • Vanderbilt University Medical Center, Nashville, Tennessee.

Zitieren

APA

Mooradian, M. J., Cai, L., Wang, A., Qiao, Y., Chander, P., & Whitaker, R. M. (2024). Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer. JAMA Network Open, 7(4), e247542. https://doi.org/10.1001/jamanetworkopen.2024.7542

Vancouver

Mooradian MJ, Cai L, Wang A, Qiao Y, Chander P, Whitaker RM. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer. JAMA Network Open. 2024;7(4):e247542. doi:10.1001/jamanetworkopen.2024.7542

BibTeX
@article{Mooradian2024,
  author = {Mooradian, Meghan J and Cai, Ling and Wang, Alice and Qiao, Yao and Chander, Pratibha and Whitaker, Ryan M},
  title = {Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {4},
  pages = {e247542},
  doi = {10.1001/jamanetworkopen.2024.7542}
}
Kostenlos starten →